These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 18633238)

  • 1. [A long-term survivor after relapsed acute myeloblastic leukemia with anthracycline dilated cardiomyopathy].
    Saito Y; Ishikawa S; Endo H; Sato Y; Susukida I; Suzuki S; Uzuka Y
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):1021-4. PubMed ID: 18633238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Severe heart failure in consequence of late anthracycline-induced cardiotoxicity--case report].
    Urbanová D; Bubanská E; Hrebík M; Mladosievicová B
    Klin Onkol; 2009; 22(1):34-7. PubMed ID: 19534438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac re-synchronization therapy in a child with severe anthracycline-induced congestive heart failure and normal QRS duration.
    Jones BO; Davis AM; Alison J; Weintraub RG; Butt W; Cheung MM
    J Heart Lung Transplant; 2007 Dec; 26(12):1333-5. PubMed ID: 18096487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-blockade intolerance in anthracycline-induced cardiomyopathy.
    Tabet JY; Meurin P; Ben Driss A; Berthaux X; Weber H; Renaud N; Cohen Solal A
    Int J Cardiol; 2006 Jan; 106(1):132-4. PubMed ID: 15992949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthracycline-induced cardiomyopathy: favourable effects of cardiac resynchronization therapy.
    Ahlehoff O; Galløe AM; Hansen PR
    Int J Cardiol; 2010 Jul; 142(2):e23-4. PubMed ID: 19135740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dilated cardiomyopathy post-chemotherapy].
    Sbrana F; Greco P; Rovai D
    Recenti Prog Med; 2009 Mar; 100(3):132-6. PubMed ID: 19475840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart Transplantation in the Short Term After Chemotherapy.
    Knecht KR; Bryant J; Garcia X; Pye S; Prodhan P; Frazier EA
    J Pediatr Hematol Oncol; 2015 Jul; 37(5):409-10. PubMed ID: 25493454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?
    Kovács GT; Erlaky H; Tóth K; Horváth E; Szabolcs J; Csóka M; Jókúti L; Erdélyi D; Müller J
    Eur J Pediatr; 2007 Nov; 166(11):1187-8. PubMed ID: 17160688
    [No Abstract]   [Full Text] [Related]  

  • 9. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anthracycline cardiomyopathy].
    Ter Arkh; 2011; 83(10):72-6. PubMed ID: 22185031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?].
    Erlaky H; Tóth K; Szabolcs J; Horváth E; Kemény V; Müller J; Csóka M; Jókúti L; Erdélyi D; Kovács G
    Magy Onkol; 2006; 50(1):25-32. PubMed ID: 16617380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart of the matter: reverse takotsubo syndrome in an anthracycline-exposed oncology patient.
    Voit J; Tibrewala A; Akhter N
    BMJ Case Rep; 2018 Oct; 2018():. PubMed ID: 30287630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.
    Creutzig U; Diekamp S; Zimmermann M; Reinhardt D
    Pediatr Blood Cancer; 2007 Jun; 48(7):651-62. PubMed ID: 17183582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of multiple biomarkers for evaluation of anthracycline-induced cardiotoxicity in patients with acute myeloid leukemia.
    Horacek JM; Tichy M; Jebavy L; Pudil R; Ulrychova M; Maly J
    Exp Oncol; 2008 Jun; 30(2):157-9. PubMed ID: 18566582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom.
    Temming P; Qureshi A; Hardt J; Leiper AD; Levitt G; Ancliff PJ; Webb DK
    Pediatr Blood Cancer; 2011 Apr; 56(4):625-30. PubMed ID: 21298750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
    Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
    Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer.
    Du XL; Xia R; Liu CC; Cormier JN; Xing Y; Hardy D; Chan W; Burau K
    Cancer; 2009 Nov; 115(22):5296-308. PubMed ID: 19672997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: a North American perspective.
    Orgel E; Zung L; Ji L; Finklestein J; Feusner J; Freyer DR
    Pediatr Blood Cancer; 2013 Sep; 60(9):1528-33. PubMed ID: 23441080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.
    Sánchez-Medina J; Gonzalez-Ramella O; Gallegos-Castorena S
    J Pediatr Hematol Oncol; 2010 May; 32(4):294-7. PubMed ID: 20404753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological manifestations of heart remodeling in anthracycline-induced dilated cardiomyopathy.
    Lushnikova EL; Klinnikova MG; Molodykh OP; Nepomnyashchikh LM
    Bull Exp Biol Med; 2004 Dec; 138(6):607-12. PubMed ID: 16134825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.